{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T10:34:21Z","timestamp":1768732461471,"version":"3.49.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,10,27]],"date-time":"2018-10-27T00:00:00Z","timestamp":1540598400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Bionomics"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1007\/s00280-018-3706-5","type":"journal-article","created":{"date-parts":[[2018,10,27]],"date-time":"2018-10-27T11:49:13Z","timestamp":1540640953000},"page":"97-105","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Phase I study of BNC105P, carboplatin and gemcitabine in partially platinum-sensitive ovarian cancer patients in first or second relapse (ANZGOG-1103)"],"prefix":"10.1007","volume":"83","author":[{"name":"For ANZGOG and HCRN Collaborative Groups","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristina","family":"Lindemann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip J.","family":"Beale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeff C.","family":"Goh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle M.","family":"Vaughan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meaghan E.","family":"Tenney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie K.","family":"Martyn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirkje","family":"Sommeijer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose L.","family":"Iglesias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriel","family":"Kremmidiotis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeremy","family":"Simpson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Doolin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tina C.","family":"Lavranos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annabell","family":"Leske","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anneso S.","family":"Veillard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Espinoza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin R.","family":"Stockler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danny","family":"Rischin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,10,27]]},"reference":[{"issue":"1","key":"3706_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/sj.bjc.6604767","volume":"100","author":"GC Kumaran","year":"2009","unstructured":"Kumaran GC, Jayson GC, Clamp AR (2009) Antiangiogenic drugs in ovarian cancer. Br J Cancer 100(1):1\u20137. \n                    https:\/\/doi.org\/10.1038\/sj.bjc.6604767","journal-title":"Br J Cancer"},{"issue":"3","key":"3706_CR2","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1007\/s00404-013-2820-1","volume":"288","author":"Q Ye","year":"2013","unstructured":"Ye Q, Chen HL (2013) Bevacizumab in the treatment of ovarian cancer: a meta-analysis from four phase III randomized controlled trials. Arch Gynecol Obstet 288(3):655\u2013666. \n                    https:\/\/doi.org\/10.1007\/s00404-013-2820-1","journal-title":"Arch Gynecol Obstet"},{"issue":"2","key":"3706_CR3","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/S1470-2045(11)70338-2","volume":"13","author":"WH Gotlieb","year":"2012","unstructured":"Gotlieb WH, Amant F, Advani S, Goswami C, Hirte H, Provencher D, Somani N, Yamada SD, Tamby JF, Vergote I (2012) Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Oncol 13(2):154\u2013162. \n                    https:\/\/doi.org\/10.1016\/S1470-2045(11)70338-2","journal-title":"Lancet Oncol"},{"issue":"1","key":"3706_CR4","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.ygyno.2011.11.021","volume":"125","author":"N Colombo","year":"2012","unstructured":"Colombo N (2012) A phase II study of aflibercept in patients with advanced epithelial ovarian cancer and symptomatic malignant ascites. Gynecol Oncol 125(1):42\u201347. \n                    https:\/\/doi.org\/10.1016\/j.ygyno.2011.11.021","journal-title":"Gynecol Oncol"},{"issue":"3","key":"3706_CR5","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1002\/cncr.28406","volume":"120","author":"WP Tew","year":"2014","unstructured":"Tew WP, Colombo N, Ray-Coquard I, Del Campo JM, Oza A, Pereira D, Mammoliti S, Matei D, Scambia G, Tonkin K, Shun Z, Sternas L, Spriggs DR (2014) Intravenous aflibercept in patients with platinum-resistant, advanced ovarian cancer: results of a randomized, double-blind, phase 2, parallel-arm study. Cancer 120(3):335\u2013343. \n                    https:\/\/doi.org\/10.1002\/cncr.28406","journal-title":"Cancer"},{"issue":"10023","key":"3706_CR6","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1016\/S0140-6736(15)01167-8","volume":"387","author":"JA Ledermann","year":"2016","unstructured":"Ledermann JA, Embleton AC, Raja F, Perren TJ, Jayson GC, Rustin GJS, Kaye SB, Hirte H, Eisenhauer E, Vaughan M, Friedlander M, Gonzalez-Martin A, Stark D, Clark E, Farrelly L, Swart AM, Cook A, Kaplan RS, Parmar MKB, ICON6 Collaborators (2016) Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 387(10023):1066\u20131074. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(15)01167-8","journal-title":"Lancet"},{"issue":"30","key":"3706_CR7","doi-asserted-by":"publisher","first-page":"3374","DOI":"10.1200\/JCO.2014.55.7348","volume":"32","author":"A Bois du","year":"2014","unstructured":"du Bois A, Floquet A, Kim JW, Rau J, del Campo JM, Friedlander M, Pignata S, Fujiwara K, Vergote I, Colombo N, Mirza MR, Monk BJ, Kimmig R, Ray-Coquard I, Zang R, Diaz-Padilla I, Baumann KH, Mouret-Reynier MA, Kim JH, Kurzeder C, Lesoin A, Vasey P, Marth C, Canzler U, Scambia G, Shimada M, Calvert P, Pujade-Lauraine E, Kim BG, Herzog TJ, Mitrica I, Schade-Brittinger C, Wang Q, Crescenzo R, Harter P (2014) Incorporation of pazopanib in maintenance therapy of ovarian cancer. J Clin Oncol 32(30):3374\u20133382. \n                    https:\/\/doi.org\/10.1200\/JCO.2014.55.7348","journal-title":"J Clin Oncol"},{"issue":"4","key":"3706_CR8","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.clon.2004.11.011","volume":"17","author":"AM Gaya","year":"2005","unstructured":"Gaya AM, Rustin GJ (2005) Vascular disrupting agents: a new class of drug in cancer therapy. Clin Oncol (R Coll Radiol) 17(4):277\u2013290","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"5299","key":"3706_CR9","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1126\/science.275.5299.547","volume":"275","author":"X Huang","year":"1997","unstructured":"Huang X, Molema G, King S, Watkins L, Edgington TS, Thorpe PE (1997) Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science 275(5299):547\u2013550","journal-title":"Science"},{"issue":"6","key":"3706_CR10","first-page":"1974","volume":"8","author":"DC Blakey","year":"2002","unstructured":"Blakey DC, Westwood FR, Walker M, Hughes GD, Davis PD, Ashton SE, Ryan AJ (2002) Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models. Clin Cancer Res 8(6):1974\u20131983","journal-title":"Clin Cancer Res"},{"issue":"1","key":"3706_CR11","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1046\/j.1365-2613.2002.00211.x","volume":"83","author":"GM Tozer","year":"2002","unstructured":"Tozer GM, Kanthou C, Parkins CS, Hill SA (2002) The biology of the combretastatins as tumour vascular targeting agents. Int J Exp Pathol 83(1):21\u201338. doi:211 [pii]","journal-title":"Int J Exp Pathol"},{"issue":"14","key":"3706_CR12","first-page":"3304","volume":"59","author":"LM Ching","year":"1999","unstructured":"Ching LM, Goldsmith D, Joseph WR, Korner H, Sedgwick JD, Baguley BC (1999) Induction of intratumoral tumor necrosis factor (TNF) synthesis and hemorrhagic necrosis by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF knockout mice. Cancer Res 59(14):3304\u20133307","journal-title":"Cancer Res"},{"issue":"2","key":"3706_CR13","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1002\/(SICI)1096-9896(199706)182:2<211::AID-PATH834>3.0.CO;2-D","volume":"182","author":"S Kumar-Singh","year":"1997","unstructured":"Kumar-Singh S, Vermeulen PB, Weyler J, Segers K, Weyn B, Van Daele A, Dirix LY, Van Oosterom AT, Van Marck E (1997) Evaluation of tumour angiogenesis as a prognostic marker in malignant mesothelioma. J Pathol 182(2):211\u2013216. \n                    https:\/\/doi.org\/10.1002\/(SICI)1096-9896(199706)182:2%3C211::AID-PATH834%3E3.0.CO;2-D","journal-title":"J Pathol"},{"issue":"9","key":"3706_CR14","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1093\/annonc\/mdq708","volume":"22","author":"M Zweifel","year":"2011","unstructured":"Zweifel M, Jayson GC, Reed NS, Osborne R, Hassan B, Ledermann J, Shreeves G, Poupard L, Lu SP, Balkissoon J, Chaplin DJ, Rustin GJ (2011) Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer. Ann Oncol 22(9):2036\u20132041. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdq708","journal-title":"Ann Oncol"},{"issue":"15","key":"3706_CR15","doi-asserted-by":"publisher","first-page":"5152","DOI":"10.1158\/1078-0432.CCR-11-0937","volume":"17","author":"D Rischin","year":"2011","unstructured":"Rischin D, Bibby DC, Chong G, Kremmidiotis G, Leske AF, Matthews CA, Wong SS, Rosen MA, Desai J (2011) Clinical, pharmacodynamic, and pharmacokinetic evaluation of BNC105P: a phase I trial of a novel vascular disrupting agent and inhibitor of cancer cell proliferation. Clin Cancer Res 17(15):5152\u20135160. \n                    https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-0937","journal-title":"Clin Cancer Res"},{"key":"3706_CR16","doi-asserted-by":"crossref","unstructured":"Leske AF, Beaumont DM, Lavranos TC, Gasic J, Kremmidiotis J (2011) Anti-tumor activity of the vascular disruption agent BNC105 in models of mesothelioma and lung cancer. In: American Association of Clinical Research, Orlando","DOI":"10.1158\/1538-7445.AM2011-3543"},{"issue":"2","key":"3706_CR17","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1097\/IGC.0b013e3182070f17","volume":"21","author":"GJ Rustin","year":"2011","unstructured":"Rustin GJ, Vergote I, Eisenhauer E, Pujade-Lauraine E, Quinn M, Thigpen T, du Bois A, Kristensen G, Jakobsen A, Sagae S, Greven K, Parmar M, Friedlander M, Cervantes A, Vermorken J, Gynecological Cancer I (2011) Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG). Int J Gynecol Cancer Off J Int Gynecol Cancer Soc 21(2):419\u2013423. \n                    https:\/\/doi.org\/10.1097\/IGC.0b013e3182070f17","journal-title":"Int J Gynecol Cancer Off J Int Gynecol Cancer Soc"},{"key":"3706_CR18","unstructured":"National Cancer Institute, US Department of Health and Human Services (2009) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. \n                    https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03\/Archive\/CTCAE_4.0_2009-05-29_QuickReference_8.5x11.pdf"},{"issue":"2","key":"3706_CR19","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228\u2013247. \n                    https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026","journal-title":"Eur J Cancer"},{"issue":"15","key":"3706_CR20","doi-asserted-by":"publisher","first-page":"3420","DOI":"10.1158\/1078-0432.CCR-14-3370","volume":"21","author":"S Pal","year":"2015","unstructured":"Pal S, Azad A, Bhatia S, Drabkin H, Costello B, Sarantopoulos J, Kanesvaran R, Lauer R, Starodub A, Hauke R, Sweeney CJ, Hahn NM, Sonpavde G, Richey S, Breen T, Kremmidiotis G, Leske A, Doolin E, Bibby DC, Simpson J, Iglesias J, Hutson T (2015) A phase I\/II trial of BNC105P with everolimus in metastatic renal cell carcinoma. Clin Cancer Res 21(15):3420\u20133427. \n                    https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-3370","journal-title":"Clin Cancer Res"},{"issue":"29","key":"3706_CR21","doi-asserted-by":"publisher","first-page":"4699","DOI":"10.1200\/JCO.2006.06.0913","volume":"24","author":"J Pfisterer","year":"2006","unstructured":"Pfisterer J, Plante M, Vergote I, du Bois A, Hirte H, Lacave AJ, Wagner U, Stahle A, Stuart G, Kimmig R, Olbricht S, Le T, Emerich J, Kuhn W, Bentley J, Jackisch C, Luck HJ, Rochon J, Zimmermann AH, Eisenhauer E (2006) Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 24(29):4699\u20134707. \n                    https:\/\/doi.org\/10.1200\/JCO.2006.06.0913","journal-title":"J Clin Oncol"},{"issue":"4","key":"3706_CR22","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1158\/1078-0432.CCR-04-1434","volume":"11","author":"JH Bilenker","year":"2005","unstructured":"Bilenker JH, Flaherty KT, Rosen M, Davis L, Gallagher M, Stevenson JP, Sun W, Vaughn D, Giantonio B, Zimmer R, Schnall M, O\u2019Dwyer PJ (2005) Phase I trial of combretastatin a-4 phosphate with carboplatin. Clin Cancer Res 11(4):1527\u20131533. \n                    https:\/\/doi.org\/10.1158\/1078-0432.CCR-04-1434","journal-title":"Clin Cancer Res"},{"issue":"15","key":"3706_CR23","doi-asserted-by":"publisher","first-page":"2823","DOI":"10.1200\/JCO.2003.05.186","volume":"21","author":"HL Anderson","year":"2003","unstructured":"Anderson HL, Yap JT, Miller MP, Robbins A, Jones T, Price PM (2003) Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate. J Clin Oncol 21(15):2823\u20132830. \n                    https:\/\/doi.org\/10.1200\/JCO.2003.05.186","journal-title":"J Clin Oncol"},{"issue":"9","key":"3706_CR24","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1038\/sj.bjc.6605650","volume":"102","author":"GJ Rustin","year":"2010","unstructured":"Rustin GJ, Shreeves G, Nathan PD, Gaya A, Ganesan TS, Wang D, Boxall J, Poupard L, Chaplin DJ, Stratford MR, Balkissoon J, Zweifel M (2010) A Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer. Br J Cancer 102(9):1355\u20131360. \n                    https:\/\/doi.org\/10.1038\/sj.bjc.6605650","journal-title":"Br J Cancer"},{"key":"3706_CR25","unstructured":"Bionomics Investigators Brochure BNC105P, version 6, vol 6"},{"issue":"3","key":"3706_CR26","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.lungcan.2013.05.006","volume":"81","author":"AK Nowak","year":"2013","unstructured":"Nowak AK, Brown C, Millward MJ, Creaney J, Byrne MJ, Hughes B, Kremmidiotis G, Bibby DC, Leske AF, Mitchell PL, Pavlakis N, Boyer M, Stockler MR (2013) A phase II clinical trial of the vascular disrupting agent BNC105P as second line chemotherapy for advanced malignant pleural mesothelioma. Lung Cancer 81(3):422\u2013427. \n                    https:\/\/doi.org\/10.1016\/j.lungcan.2013.05.006","journal-title":"Lung Cancer"},{"issue":"20","key":"3706_CR27","doi-asserted-by":"publisher","first-page":"3323","DOI":"10.1200\/JCO.2009.25.7519","volume":"28","author":"E Pujade-Lauraine","year":"2010","unstructured":"Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, Gebski V, Heywood M, Vasey PA, Volgger B, Vergote I, Pignata S, Ferrero A, Sehouli J, Lortholary A, Kristensen G, Jackisch C, Joly F, Brown C, Le Fur N, du Bois A (2010) Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol 28(20):3323\u20133329. \n                    https:\/\/doi.org\/10.1200\/JCO.2009.25.7519","journal-title":"J Clin Oncol"},{"issue":"1","key":"3706_CR28","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.ccr.2006.11.020","volume":"11","author":"C Calabrese","year":"2007","unstructured":"Calabrese C, Poppleton H, Kocak M, Hogg TL, Fuller C, Hamner B, Oh EY, Gaber MW, Finklestein D, Allen M, Frank A, Bayazitov IT, Zakharenko SS, Gajjar A, Davidoff A, Gilbertson RJ (2007) A perivascular niche for brain tumor stem cells. Cancer Cell 11(1):69\u201382. \n                    https:\/\/doi.org\/10.1016\/j.ccr.2006.11.020","journal-title":"Cancer Cell"},{"issue":"3","key":"3706_CR29","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.stem.2007.06.002","volume":"1","author":"PC Hermann","year":"2007","unstructured":"Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, Guba M, Bruns CJ, Heeschen C (2007) Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 1(3):313\u2013323. \n                    https:\/\/doi.org\/10.1016\/j.stem.2007.06.002","journal-title":"Cell Stem Cell"},{"issue":"11","key":"3706_CR30","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.4161\/15384047.2014.956605","volume":"15","author":"DJ Inglis","year":"2014","unstructured":"Inglis DJ, Lavranos TC, Beaumont DM, Leske AF, Brown CK, Hall AJ, Kremmidiotis G (2014) The vascular disrupting agent BNC105 potentiates the efficacy of VEGF and mTOR inhibitors in renal and breast cancer. Cancer Biol Ther 15(11):1552\u20131560. \n                    https:\/\/doi.org\/10.4161\/15384047.2014.956605","journal-title":"Cancer Biol Ther"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-018-3706-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-018-3706-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-018-3706-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,26]],"date-time":"2019-10-26T19:25:50Z","timestamp":1572117950000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-018-3706-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,27]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["3706"],"URL":"https:\/\/doi.org\/10.1007\/s00280-018-3706-5","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,27]]},"assertion":[{"value":"9 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Dr. Lindemann, Dr. Veillard, Dr. Espinoza. Dr. Sommeijer, Dr. Rossi, Dr. Simpson, Dr. Tenney, Dr. Goh and Dr. Vaughan declare that they have nothing to disclose. Dr. Lavranos, Ms. Doolin, Ms. Leske and Dr. Kremmidiotis report salary\/stakeholder from Bionomics Limited, outside the submitted work. Dr. Iglesias reports salary from Bionomics Limited, outside the submitted work and has a patent on BNC105 pending. Dr. Martyn reports Grants and non-financial support from Bionomics, during the conduct of the study. Dr. Beale reports personal fees from Roche, personal fees from Astra Zeneca, Grants from Roche, outside the submitted work. Dr. Rischin reports a Grant from Bionomics to ANZGOG for the research costs of the study; in addition, Dr. Rischin has a patent B55 (US) BNC105 Triple Combination Patent Application pending and trial steering\/scientific advisory committees\u2014Bionomics, Merck, Amgen, Regeneron, Bristol-Myers\u2014all uncompensated. Dr. Stockler reports Grants from Bionomics, during the conduct of the study; Grants from Bayer, Grants from BMS, Grants from Astra Zeneca, Grants from Specialised Therapeutics, Grants from Amgen, Grants from Astellas, Grants from Merck, outside the submitted work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in this study were in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki declaration and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}